Table 5.
Six-month progression risk to ESKD and HF composite by change in RAASi dose following an HK episode
| RAASi change | Event | US | Japan | ||||
|---|---|---|---|---|---|---|---|
| 6-month risk, % (95% CI) | Patient count | Events (N) | 6-month risk, % (95% CI) | Patient count | Events (N) | ||
| Maintained or up-titrated | Progression to ESKDa in patients with CKD stage 3 or 4 | 3.2 (2.7–3.8) | 4586 | 138 | 5.3 (3.7–6.9) | 793 | 41 |
| Down-titrated | 5.4 (3.2–7.5) | 460 | 23 | – | 63 | – | |
| No prescription | 5.8 (4.9–6.8) | 2460 | 138 | 8.1 (5.1–11.0) | 323 | 26 | |
| Maintained or up-titrated | HF compositeb in patients with HF | 14.6 (13.3–15.9) | 3049 | 421 | 11.7 (10.5–13.0) | 2617 | 304 |
| Down-titrated | 20.8 (16.7–24.7) | 430 | 84 | 18.9 (14.1–23.4) | 278 | 52 | |
| No prescription | 20.6 (18.7–22.4) | 1966 | 392 | 16.2 (14.2–18.0) | 1460 | 234 | |
CI Confidence interval, CKD Chronic kidney disease, ESKD End-stage kidney disease, HF Heart failure, HK Hyperkalemia, RAASi Renin-angiotensin-aldosterone system inhibitor
Events (N), number of events at 6 months
aIncluding diagnosis of CKD stage 5/ESKD or initiation of hemodialysis
bHospitalization for HF, emergency visit for HF